Replies to post #7194 on Revance Therapeutics Inc (RVNC)

[YY1000]

KOLs are charging patients 50% to 75% more for Daxi versus Botox and purchasing Daxi for less than Botox.

Correct and I find this puzzling... This seems to be one of the lingering negative effects of the premium price launch strategy.

large multi unit practices make up over 50% of the Botox sales. KOLs write most of the white papers but do very little of the injections.

Big medspa chains are in a different category but with the KOLs, other doctors, PAs, NPs the practices where these doctors work are among the largest dermatologist users of toxins.